CagriSema is a new medication in development from Novo Nordisk. It builds on Wegovy by adding a second drug to the mix.
Quick Comparison
| Wegovy | CagriSema | |
|---|---|---|
| Active drug | Semaglutide | Semaglutide + Cagrilintide |
| Drug class | GLP-1 agonist | GLP-1 + Amylin agonist |
| FDA approval | Weight management (approved) | In clinical trials |
| Dosing | Once weekly | Once weekly (in trials) |
| Status | Available now | Not yet FDA-approved |
What Makes CagriSema Different?
CagriSema combines:
- Semaglutide — the same drug in Wegovy (GLP-1 agonist)
- Cagrilintide — an amylin receptor agonist that also signals fullness
Two fullness signals instead of one. That's the idea.
Weight Loss Results
From clinical trials:
- Wegovy: ~15% body weight loss on average
- CagriSema (in trials): ~20-25% body weight loss
CagriSema has shown stronger results. The added cagrilintide appears to boost weight loss beyond what semaglutide alone can do.
Side Effects
Based on trial data, CagriSema causes similar side effects:
- Nausea
- Decreased appetite
- Vomiting
- Diarrhea or constipation
Because it hits two pathways, side effects may be stronger for some people. More real-world data is needed.
Availability
CagriSema is not yet FDA-approved. Novo Nordisk is running Phase 3 trials. If approved, it would likely launch as a weight loss medication.
Cost
No pricing yet. It will likely be priced similarly to Wegovy (~$1,350/month).
Who Might Benefit?
- People who plateau on Wegovy
- People who want stronger weight loss
- People who prefer Novo Nordisk products
Bottom Line
CagriSema could offer stronger weight loss than Wegovy by combining two drugs. It's not available yet, but worth watching.
If Wegovy is working for you now, there's no reason to wait. If you're not getting the results you want, talk to your doctor about current options.
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.
